|

Diet and Cognitive Training in Hematologic Cancer Survivors

RECRUITINGN/ASponsored by University of Alabama at Birmingham
Actively Recruiting
PhaseN/A
SponsorUniversity of Alabama at Birmingham
Started2022-11-22
Est. completion2026-12-31
Eligibility
Age21 Years+
Healthy vol.Accepted
Locations1 site

Summary

The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are: * is it feasible to combine a ketogenic diet supplementation and online cognitive training in an intervention program * will patients using the combined intervention program have improved cognitive functioning compared to those who don't use it * how long will the intervention programs effects last Participants randomized to the intervention arm will consume an exogenous ketogenic supplementation and use an online cognitive training program for 12 weeks, while waitlist arm functions as a control group and will receive the online cognitive training only after a wait period of 12 weeks. Researchers will compare the intervention and waitlist control groups to see if the intervention improves cognitive functioning.

Eligibility

Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult with hematologic malignancy diagnosed at age ≥21 years
* Outpatient at least 3 months from completion of blood or marrow transplant (BMT) or at least 6 months from diagnosis for patients not treated with BMT
* Evidence of mild-to-moderate cognitive impairment using either the Modified Telephone Interview for Mild Cognitive Impairment (TICS-M) or PROMIS 8a short form raw score = 19 -37
* Have daily access to an internet-connected home computer
* Can fluently read and write in English
* Can understand and sign the study-specific Informed Consent Form

Exclusion Criteria:

* History of pre-existing neurological disorder or documented major psychiatric disorder
* Significant auditory, visual, or motor impairments
* History of color blindness
* Participated in neuropsychological intervention within the past 6 months
* Evidence of active chronic graft vs. host disease (GvHD) for allogeneic BMT
* History of pre-existing metabolic disease
* Allergies to soy or milk
* Body Mass Index (BMI) ≤20

Conditions3

CancerCognitive ImpairmentHematologic Malignancy

Locations1 site

University of Alabama at Birmingham
Birmingham, Alabama, 35233
Noha Sharafeldin, MD, MSc, PhD2056382144nsharafeldin@uabmc.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.